Vera Therapeutics (VERA) Cash from Restructuring (2020 - 2021)
Vera Therapeutics posted quarterly Cash from Restructuring of $124000.0 for Q4 2021, down 94.69% year-on-year from $2.3 million in Q4 2020, and down 0.8% on a QoQ basis from $125000.0 in Q3 2021.
Vera Therapeutics (VERA) has 2 years of Cash from Restructuring data on file, last reported at $124000.0 in Q4 2021.
- For the quarter ending Q4 2021, Cash from Restructuring fell 94.69% year-over-year to $124000.0; the trailing twelve-month figure through Sep 2022 stood at $124000.0 (down 96.14% YoY), and the FY2021 full-year result was $999000.0, down 58.77% from the prior year.
- Cash from Restructuring for Q4 2021 stood at $124000.0, down from $125000.0 in the prior quarter.
- Across five years, Cash from Restructuring topped out at $2.3 million in Q4 2020 and bottomed at $29000.0 in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vera Therapeutics | 2.43 Bn | 1.83 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 124,000.00 |
| Sep 30, 2021 | 125,000.00 |
| Jun 30, 2021 | 160,000.00 |
| Mar 31, 2021 | 590,000.00 |
| Dec 31, 2020 | 2.34 Mn |
| Sep 30, 2020 | 30,000.00 |
| Jun 30, 2020 | 29,000.00 |
| Mar 31, 2020 | 29,000.00 |